Next Article in Journal
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study
Next Article in Special Issue
Safety and Efficacy of High-Dose Chemotherapy with TreoMel 200 vs. TreoMel 140 in Acute Myeloid Leukemia Patients Undergoing Autologous Stem Cell Transplantation
Previous Article in Journal
The Role of Cancer Stem Cell Markers in Ovarian Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 16
Issue 1
10.3390/cancers16010042
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances

by
Martina Canichella
1,*,
Matteo Molica
2,
Carla Mazzone
1 and
Paolo de Fabritiis
1,3
1
Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy
2
Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, Italy
3
Department of Biomedicina e Prevenzione, Tor Vergata University, 00133 Rome, Italy
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(1), 42; https://doi.org/10.3390/cancers16010042
Submission received: 8 November 2023 / Revised: 7 December 2023 / Accepted: 15 December 2023 / Published: 20 December 2023
(This article belongs to the Special Issue 2nd Edition of New Therapeutic Strategies for Acute Myeloid Leukemia)
Browse Figures
Review Reports Versions Notes

Abstract

:

Simple Summary

Compared to the resounding success demonstrated in the field of B-cell leukemia, lymphoma, and multiple myeloma, in the field of acute myeloid leukemia, CAR-T-cell-therapy slows down its application in clinical practice. Yet, immunotherapy and/or cell therapy could be curative in certain high-risk AML subtypes refractory to classical chemotherapy approaches. Several CAR-T constructs targeting different antigens have been tested and have shown promising results. This review illustrates the main results obtained with the use of CAR-T in AML.

Abstract

Chimeric antigen receptors (CAR)-T-cell therapy represents the most important innovation in onco-hematology in recent years. The progress achieved in the management of complications and the latest generations of CAR-T-cells have made it possible to anticipate in second-line the indication of this type of treatment in large B-cell lymphoma. While some types of B-cell lymphomas and B-cell acute lymphoid leukemia have shown extremely promising results, the same cannot be said for myeloid leukemias—in particular, acute myeloid leukemia (AML), which would require innovative therapies more than any other blood disease. The heterogeneities of AML cells and the immunological complexity of the interactions between the bone marrow microenvironment and leukemia cells have been found to be major obstacles to the clinical development of CAR-T in AML. In this review, we report on the main results obtained in AML clinical trials, the preclinical studies testing potential CAR-T constructs, and future perspectives.

1. Introduction

Acute myeloid leukemia (AML) is a hematological malignancy characterized by the clonal proliferation of immature and non-functional myeloid cells in bone marrow and blood. It represents the second most common form of leukemia in adults [1]. AML can be considered a heterogeneous disease with different morphological, genetic, cytogenetic, and clinical characteristics. It can onset de novo after the evolution of a previous myeloid disease or after previous chemo or radiotherapy (so-called therapy-related AML).
Despite the high rate of complete remission (CR) achieved after first line therapy (about 60–70% of patients), the overall survival rate of refractory/relapsed (R/R) AML patients remains too low (25% at 5 years) [2]. For high-risk patients, the only therapeutic option is allogeneic hematopoietic stem cell transplantation (allo-HSCT), although it is not accessible for all patients, especially the elderly. Immunotherapy-based approaches promise higher survival rates due to greater positive responses, lower toxicity (which allows more patients to be fitter and transplant-eligible), and a lower rate of minimal residual disease (MRD). However, there are difficulties in obtaining these desired results, which can be traced back to three main causes: the lack of a specific AML surface antigen, tumor heterogeneity, and the complexity of the bone marrow microenvironment. In fact, it is well known that the stromal cells network may preserve AML cells from the damage of chemo or cellular therapy. In recent years, a novel form of cellular immunotherapy has been explored based on the engineering of autologous T-cells expressing a chimeric antigen receptor (CAR) against tumor antigens. In the hematological field, CAR-T-cell therapy had produced significant results in the treatment of R/R diffuse large B-cell lymphoma (DLBCL), mantle-cells lymphoma (MCL), follicular lymphoma, B-cell acute lymphoblastic leukemia (B-ALL), and R/R multiple myeloma (MM) [3,4,5,6,7,8,9,10,11,12,13]. Unfortunately, the immunological complexity of AML makes it difficult to apply CAR-T in AML patients, both in preclinical model trials and in clinical practice. For this review, we retrospectively searched PubMed databases and meeting abstracts for clinical and preclinical applications of CAR-T in AML.

2. The Structure of CARs

From the first CAR designed by Zelig Sahar et al. in 1989, the basic structure remained the same. It consists of four domains (Figure 1) [14]:
  • Antigen recognition domain
  • Hinge domain
  • Transmembrane domain
  • Intracellular signal domain
Cancers 16 00042 g001
Figure 1. Basic structure of CAR-T.
Figure 1. Basic structure of CAR-T.
Cancers 16 00042 g001

2.1. Antigen Recognition Domain

The extracellular antigen recognition domain is fundamental for CAR-T-cell activation. The most common structure is similar to the single-chain variable fragment (skiff) monoclonal antibodies. It is composed of two chains the heavy (VH) and light (VL). Most innovative CAR constructs used antibody-derived binding components such as nanobodies. This part of the CAR receptor allows for antigen binding, antigen recognition, and cytotoxicity [15,16,17].

2.2. Hinge Domain

The hinge domain can be considered as a bridge between the extracellular (which connect the antigen recognition domain) and the transmembrane domains. Its main property is flexibility, which is responsible for CAR and expression, signal transduction, and epitope recognition. Currently, the most common hinge domains used for the CAR construct are represented by amino acid sequences derived from CD8, CD28, IgG1, or IgG4.

2.3. Transmembrane Domain

The transmembrane is probably the region less focused on, but this domain is also important for the correct functioning of CAR-T. The most common structures derived from natural proteins include CD3ζ, CD4, CD8α, or CD28. There is evidence about different characteristics of each of them. For example, CD3ζ facilitates CAR dimerization and activation through the incorporation of the endogenous TCRs [17,18]. Indeed, it seems that the type of transmembrane domains influence CAR-T-cell cytokine production. CD8a induces less IFNγ and TNFα release than CD28 and the activation-induced cell death (AICD) [19].

2.4. Intracellular Signal Domain

The function of the intracellular signal domain is the activation of T-cell engineer. This is possible with the combination of the activation domain and one or more co-stimulatory factors. The CD3z is the template of the activation part, but it is not sufficient to promote the persistence and activity of CAR-T [20].
The addition of co-stimulatory domains resulted in the better performance of CAR-T [21]. CD28 and 4-1BB are the two most utilized costimulatory domains used in the development of CAR-T approved by the FDA and EMA [3,4,5,6,7,8]. Currently, other costimulatory molecules are being tested in preclinical model KIR2DS2 (killer cell immunoglobulin-like receptor 2DS2), ICOS (inducible T-cell co-stimulator), CD27, MYD88-CD40, and OX40 (CD134) [22,23,24,25,26,27].

3. CAR-T Generations

To date, research has led to the development of five generations of CAR-T-cells based on variations in co-stimulatory molecules (Figure 2).
The first generation included CAR with CD3ζ without co-stimulatory domains. This construct failed in the persistence and activity of CAR-T-cells in vivo [24]. The second generation, as cited above, presented the additional co-stimulatory domains CD28 and 4-1BB, and they represented the CAR-T currently approved for clinical practice [25]. Then, to improve safety, a third generation was developed with the addition of multiple co-stimulatory domains. However, this does not translate to a significant success compared with the second generation. [26]. The fourth generation CAR is represented by T-cells redirected for universal cytokine-mediated killing (TRUCKs) with an added IL-12. IL-12 is expressed either constitutively or inducible after CAR activation, and support the elimination of malignant cells through mechanisms [27,28]. Finally, the fifth generation CAR was designed to involve the IL-2 receptor in the structure. This construct can activate three pathways (TCR, CD28 and JAK-STAT), which enhance the expansion of CAR-T [29,30,31].

4. CAR-T in Clinical Phase in AML

In theory, the ideal target antigen for CAR-T-cell therapy should have four principal characteristics:
  • Expression in the majority of patients
  • Expression on blasts and on immature leukemia initiating clones
  • Stable expression without downregulation
  • Absent on normal hematopoietic stem cells (HSC) and other normal tissue to avoid off-target effects
So far, no antigen on AML cells fulfills all criteria. Researchers have focused on several tumor antigens, but only a minority of them have resulted in effective targets for CAR. In Table 1, we report the clinical trial currently open to recruitment, while in Table 2, we report the results of the mail trials that have been published [32]. Finally, Table 3 summarizes the main AML target antigens used in clinical trials and in preclinical models.

4.1. CD33-CAR T-Cell

CD33 is a transmembrane receptor belonging to the sialic-acid-binding immunoglobulin-like lectin (Siglec) family. It is expressed both on myeloid progenitors and on differentiated cells [33]. About 90% of AML leukemic cells (both stem cells and blasts) express CD33, making it a suitable target [33]. Regarding the anti-CD33 CAR-T experience, after the first publication by Wang et al., different researchers have focused on the in vitro and in vivo efficacy of this construct [33]. Kenderian et al. developed a CD33 CAR (CART33) using the scFv of gentuzumab-ozogamicin. CART33 exhibited significant cytotoxicity in vitro and in xenograft model. However, the most common adverse effect was the irreversible aplasia [56]. To overcome the myelosuppression after CAR-T therapy, Minagawa et al. designed selectively inducible Caspase-9-CAR-T-cells which could specifically lyse CD33+ AML cells in vitro, largely eliminating CAR-T-cells by suicide gene activation [40]. Then, Li et al. demonstrated that 4-1BB as a co-stimulator domain increased central memory and prolonged survival compared with CD28 [57]. Subsequently, Zheng et al. used PI3K inhibitors to modulate the differentiation of CD33 CAR-T [58]. The history of CD33 CAR-T continues with Tambaro et al., which in 2011 conducted a phase I clinical trial to evaluate the efficacy and safety of CD33 CAR-T in R/R AML [59]. Then, in 2022, Liu et al. demonstrated that the third generation CD33 CAR-T exhibited stronger vitality, proliferation, and cytotoxicity than the second-generation [60]. However, the efficacy of CD33 CAR-T in vitro did not translate to promising results in clinical trials. More efforts are needed to improve the anti-leukemia response of CD33 CAR T in AML patients, and hopefully, we may see positive results in the ongoing clinical trials.

4.2. CD123-CAR T-Cell

CD123 is an IL-3 receptor alpha chain that acts as is normally expressed on HSC [44,45,61,62]. Indeed, this antigen is expressed in about 97% of AML patients and in 45% of these patients, it is overexpressed. Low levels of CD123 were observed on monocytes, dendritic cells, and endothelial cells [63]. In vitro and preclinical evidence demonstrated that CD123 CAR-T was effective against AML blasts without eliminating granulocytes/macrophages and erythroid colony formation [64]. However, Gill et al. demonstrated that the efficacy of CD123 CAR-T is associated with myeloablation in a xenograft mouse model, suggesting that CD123 CAR-based treatment may be used as a bridge for HSCT [65]. The first clinical application of CAR123 confirmed its anti-leukemic activity; however, two major issues emerged [66]. The first was the need to allograft post CAR123 treatment due to myeloablation. The second was the scarce persistence of CAR products, which may lead to AML progression. To address these challenges, different strategies were designed, including (1) transient activation of anti-CD123 with a messenger RNA electroporated platform; (2) T-cell depletion with alemtuzumab (monoclonal antibody against CD52) after CAR-T-cell therapy; and (3) T-cell ablation with rituximab to CD20-coexpressing CART123 (CART123-CD20) [67,68]. Indeed, Arcangeli et al. introduced a mutation in the anti-CD123 CAR antigen binding gene to decrease the affinity of CAR and minimize its toxicity and side effects [35,69]. These approaches together seem to be promising, and several clinical trials are currently exploring the feasibility of CAR123. Meanwhile, in recent years, CD123 seems to be a more effective target when used in an allogeneic CAR-T approach (see below).

4.3. CLL1-CAR T-Cell

C-type lectin-like molecule-1 (CLL-1) is a type II transmembrane glycoprotein expressed in about 92% of AML blasts and leukemia stem cells (LSCs), and absent in normal CD34+CD38-HSCs [70,71]. This expression pattern makes it a potential target for therapeutic intervention. The first in vitro experiments of CLL1-CAR by Tashiro et al. demonstrated a high efficacy in killing AML blasts without damaging healthy HSCs, allowing immune recovery after therapy [72]. The first report on the use of CLL1-CAR in an AML pediatric patient was by Liu et al. Compound CAR-T targeting CLL1 and CD33 was constructed, and alemtuzumab was administered with the goal of clearing CAR-T-cells after tumor eradiation. The patient received two split doses of CAR-T and achieved CR on day 19 [46]. Subsequent research focused on designing a different CLL1 CAR construct with better proliferation, functional persistence, and antitumor activity. Atilla and colleagues found that CD28ζ CAR with a short hinge region or with a CD8 intracellular domain produced better results than other CLL1 CARs [73]. They also demonstrated that CLL1 CAR with additional transgenic IL15 supplementation and a Caspase-9 control switch showed expansion, persistence, and anti-leukemia activity without excessive cytokine production. Further observations showed that PD-1 expression increased after the activation of CAR-T-cells and caused T-cell exhaustion. To overcome this issue, Lin et al. designed a PD1-silenced CLL-1 CAR and observed the same cytotoxicity with longer persistence [74]. Overall, CLL1-CAR shows promising anti-tumor efficiency in pre-clinical experiments and anti-AML cytotoxicity in spared normal HSCs [75].

4.4. CD70-CAR T-Cell

CD70, a member of the TNF-alpha family, represents an optimal target against AML because it is absent on HSCs, but highly expressed on myeloid blasts and on LSCs [76,77]. The history of CD70 CAR began with the observation by Reither et al. that the CD70/CD27 axis promotes the stemness of AML blasts, and at the same time, they demonstrated that a hypomethylating agent (HMA) upregulated CD70 expression in LSCs [41]. This evidence led to a phase I trial combining cusatuzumab (anti-CD70 monoclonal antibody) with azacytidine. Although this study reported a high CR rate, it was not confirmed in the subsequent phase II trial. However, these experiments opened the way to the development of CD70-specific CAR-T [78]. Sauer et al. designed the first generation of CD70-CAR T (full length-CD27), which proved effective against AML blasts [79]. Wang et al. subsequently developed a second-generation CAR that included a 4-1BB costimulatory domain and CD3ζ, which together conferred the highest IFNγ production [51]. More recently, Leick et al. focused on the hinge region [52]. Based on this evidence from the combination of AZA with cusatuzumab, AZA may also be used as a bridge in the treatment of patients with R/R AML to CD70-CAR T-cells. However, the safety and efficacy of CD70 CAR needs more evidence in clinical trials.

4.5. NKG2D Ligands-CAR T-cell

NKG2D is an activator receptor with a homodimer and hexamer form expressed on CD8+ T-cells, a small amount of CD4+ cells, γδ T-cells, NK cells, and NKT-cells. NKG2D has a wide spectrum of ligands that are overexpressed encountering DNA damage, infections, and malignant transformations, namely MICA, MICB, and UL16-binding proteins (ULBP) [80,81]. Therefore, NKG2D ligands in CAR-T-cells have the potential for applications. The first evidence of NKG2D ligands CAR efficacy was derived from murine studies by Sentman and colleagues, which demonstrated the eradication of MM, lymphoma, and ovarian cancers [82]. Baumeiste et al. conducted a phase I clinical trial with first-generation NKG2D-CD3ζ-CAR-T in AML and MDS patients [37]. One AML patient exhibited a high level of IFN-γ without any high-grade toxicities. There are no on-going clinical trials with NKGD2-CAR T [83]; however, further studies will be required to prove the efficacy and safety of NKGD2 CAR-T.

4.6. FLT3-CAR T-Cell

FMS-like tyrosine kinase 3 (FLT3) is a member of the class III receptor tyrosine kinases, mainly expressed on the cell surface of hematopoietic progenitor cells, and plays an important role in normal hematopoiesis such as proliferation, differentiation, and survival [84,85]. However, about 30% of AML have FLT3 gene mutations (internal tandem duplications (ITD) and alterations in the tyrosine kinase domain (TKD)) [86]. However, the ectodomain of the FLT3 molecule is usually spared. Indeed, hematopoietic cells expressed FLT3 at low levels, making it a suitable marker for immunotherapy. In a preclinical study, a second-generation FLT3 4-1BB-CD3-CAR T-cell demonstrated the ability to recognize and eliminate FLT3+ tumor cells. At the same time, no toxicity assessment in a xenograft model was observed [87]. In another preclinical study, Wang et al. demonstrated the ability of FLT3L-4-1BB-CD3ζ-CAR T-cells to target FLT3L+ leukemia cells [88]. This experiment confirmed the previous results with less off-tumor toxicity on healthy progenitors and HSCs.

4.7. CD7-CAR T-Cell

CD7 is a transmembrane glycoprotein expressed in T-cells, NK cells with a co-stimulatory role in B- and T-cell lymphoid interactions. CD7 is also expressed in around 30% of AML patients, but not in healthy myeloid cells. For engineered CAR T-cells, CD7 removal is mandatory to limit T-cell fratricide due to CD7 expression by T-cells [89]. Gomes-Silva et al., developed a CD7-CAR T-cell, which was engineered against CD7+ tumor cells using the CRISPR/Cas9 technique to remove the CD7 gene [90]. Subsequently, a second generation of CD7-knockout (CD7KO) CD28- CD3ζ- CD7-CAR T-cell was designed. The results showed high cytolytic effects against AML, and surprising elimination of primary AML blasts and leukemia colony-forming cells, sparing healthy and erythroid cells. These results suggest that CD7-CAR T-cells are a potent weapon for refractory or relapsed AML.

5. Potential CAR-T in Preclinical Phase in AML

In the field of AML research, there is a constant effort to identify novel target antigens and corresponding CAR-binding domains with potential therapeutic utility. The major challenge is to identify an antigen with no or low expression in HSCs to avoid CAR T-related myelosuppression. Because there is often an overlap of antigen expression between HSCTs and blasts, different mechanisms have been adopted to overcome this limitation. In recent years, different CAR-T-cells against promising antigens have been designed, and these have demonstrated efficacy in in vitro and in vivo models; however, the majority have not yet been tested in clinical trials.

5.1. FRβ-CAR T-Cell

The folate receptor (FR) family is a group of folate-binding protein receptors including four members (α, β, γ and δ) with different tissue distributions. In particular, FRα and FRβ are commonly upregulated in ovarian cancer and AML, respectively. FRα-specific CAR-T-cells were developed more than 20 years ago, and currently, 4-1BB co-stimulated CAR-T are being evaluated in clinical trials in patients with ovarian cancer [91]. FRβ is an attractive target because it is expressed on about 70% of primary AML blasts and is limited in normal tissue. Preclinical models demonstrate that FRβ can be upregulated by all-trans retinoic acid (ATRA), a drug approved for the treatment of acute promyelocytic leukemia. Given these unique characteristics, Lynn and colleagues developed and characterized FRβ-specific CAR constructs containing the m909 scFv which had been previously validated for recognition of human FRβ [47]. They found that m909-CAR T activation directly correlated with the expression of FRβ; in the presence of low FRβ levels, CAR activity was decreased as demonstrated by the reduction of IFNγ and cytolysis. In contrast, exposure of FRβ+ AML to ATRA upregulates the FRβ expression, resulting in higher IFNγ production and increased cytolytic activity. Interestingly, the ATRA-mediated induction of FRβ did not impact FRβ expression in healthy HSCT and m909 CAR T-cells, limiting the off-target effect. FRβ is a promising target for CAR-T-cell therapy, which may be augmented in combination with ATRA.

5.2. h8F4-CAR T-Cell

It is well known that in AML blasts, the PR1 peptide derived from the leukemia-associated antigen proteinase 3 is overexpressed in HLA-A2 cells. Molldream et al. observed that in vitro PR1-induced cytotoxic T lymphocytes (CTLs) recognized myeloid blasts [92]. Subsequently, Ma et al. developed an anti-PR1/HLA-A2-second generation CAR-T-cell using ScFv derived from an anti-PR1/HLA-A2 T-cell receptor (TCR)-like antibody, called h8F4 [93]. This PR1-CAR-T exhibited high cytotoxicity against AML blasts in vitro while sparing normal hematopoietic progenitors. These results suggest the potential of endogenous self-antigens for targeting by CAR-T-cells in AML patients; however, clinical tests are needed to confirm their effectiveness and safety profile.

5.3. WT1-CAR T-Cell

Wilms Tumor 1 (WT1) is an oncogenic, zinc-finger transcription factor. WT1 is important for different cellular processes such as organ development, differentiation, and apoptosis. Its expression is low in bone marrow, the kidney, gonads, and spleen, and it is overexpressed in various hematological malignancies (AML and CLL) and in several solid tumors (glioblastoma, mesothelioma and ovarian cancer) [39,94,95]. Rafiq et al. developed and tested WT1-CAR-T-cells as another TCR mimic CAR using HLA-A*02:01, a peptide that arose from the WT1 antigen [48]. The efficacy of this construct has been demonstrated in the lysis activity and secretion of IL-2 and IFN-γ against cell lines in an in vitro model. Further experiments and in vivo studies are necessary to confirm the robustness of this target.

5.4. LILRB4-CAR T-Cell

LILRB4, a leukocytic, immunoglobulin-like receptor-B family, is a potential target antigen in AML. In a preclinical experiment, 41BB-CD3ζ-anti-LILRB4-CAR-T was engineered using the humanized ScFv to specifically target LILRB4 AML cells. The results were interesting due to the potent cytotoxic activity against AML blasts, together with a reduction in off-tumor toxicity by sparing normal progenitors and HSCs [96].

5.5. CD84-CAR T-Cell

A potential new target in the development of CAR T-cells in R/R AML is CD84, an immunoreceptor member of SLAM family (SLAMF5). Similar to CD123, CD84 is overexpressed on the surface of AML cells, but is low in CD34+ HSC and absent in other tissue. These features make CD84 a suitable target to design CAR-T. Pèrez-Amill et al. developed a CD84 CAR T using both human and murine CD84-binding sequences, resulting in six different constructs [97]. In vitro experiments demonstrated cytotoxicity against an AML cell line while sparing healthy HSCs. These results were confirmed using two of the six CD84-CAR-T in a NSG xenograft mouse model. CD84 CAR-T has the potential to become an efficient and safe treatment for AML.

5.6. Siglec-6-CAR T-Cell

Siglec-6 is expressed in myeloid leukemic blasts, but is absent on normal HSC cells. Siglec-6 consists of three extracellular immunoglobulin (Ig) domains and two intracellular immunoreceptor tyrosine-based inhibition motifs (ITIMs). ITIM motifs are fundamental for regulating and activating functions in immune cells [49,55]. Siglec-6 is also expressed in B-cells, mast cells, and placenta cells, but are absent on T-cells, natural killer (NK) cells, neutrophils, macrophages, and monocytes. In AML, it is expressed in primary AML blasts and absent in normal HSCs. Jetani et al. developed a Singlec-6 CAR T with a targeting domain derived from the mAb JML-1 [98]. In vitro and in vivo experiments revealed a high effectiveness against AML blasts, without impairing normal HSC activity. These preliminary results suggest that Siglec-6 CAR-T may be an important novel potent target in AML treatment; however, it requires much more investigation.

5.7. TIM-3 CAR T

T-cell immunoglobulin mucin-3 (TIM-3) is an immune checkpoint protein expressed on the membrane of leukemia stem cells, which can inhibit cancer immunity [99]. TIM-3 as a surface molecule is expressed on LSCs in almost all types of AML, but not on HSCs. The injection of TIM-3(+) AML cells into immunodeficient mice led to AML reconstitution, and these data—plus the observation that TIM-3 is not expressed in normal tissues and HSCs—make it an attractive target. Utilizing scFv from a TIM antibody, a second generation TIM3 CAR-T was developed. In xenograft models, TIM3 CAR-T showed high antileukemia activity with the production of IFN-γ, granzyme B, and perforin. Xin He et al. demonstrated in a mouse model the efficacy and low toxicity of CAR-T-cells, specifically targeting both CD13 and TIM3 that are upregulated in LSCs [100]. Further experiments on TIM-3 could lead to the development of an effective AML CAR treatment.

5.8. CD93 CAR-T-Cell

CD93 is a C-TYPE lectin transmembrane receptor, and it can be considered an adhesion molecule. Among AML antigen markers used to monitor minimal residual disease, CD93 showed an interesting expression profile due to its presence in AML blasts and its absence in other immune cells [42,50]. Richards et al. designed a CD93 CAR-T using a humanized CD93-specific binder [101]. Their results showed strong anti-leukemic activity while sparing healthy HSCs. However, the presence of CD93 on the surface of endothelial cells led to an important “off-target” toxicity. To address the challenge of endothelial-specific cross-reactivity, a model based on NOT-gated CD93-CAR T-cells was developed that circumvented endothelial cells. In this model, endothelial cells were protected and not damaged from CD93 CAR T. CD93 represents a potentially effective target for CAR-T in AML treatment; however, the cross-reactivity against endothelial cells is a challenging problem to overcome [101].

6. CAR-T-Cells Side-Effects

The success of CAR-T-cell therapy also depends on the management of the specific toxicities which are illustrated below, and on the strategy to overcome CAR-T limitations (Section 7). In these two sections, we reported the consolidated date regarding the toxicity derived from the pivotal CAR-T trials in which NHL, LAL-B and MM were treated in patients. However, as shown in Table 3, the most common side effects in the treatment of AML patients with CAR-T are represented by cytokine release syndrome (CRS) and immune-effector-cell-associated neurotoxicity syndrome (ICANS). Indeed, in the case of CAR-T constructs that are expressed both on blast cells and on HSCT, myelosuppression was observed.

6.1. Cytokine Release Syndrome (CRS)

Considering all grades, around 77–93% of leukemia patients and 37–93% of lymphoma patients receiving CAR-T-cell therapy manifested CRS [3,4,5,6,7,8,9,10,11,12]. CRS is triggered by inflammatory cytokines and chemokines released by CAR-T-cells, such as interferon (IFN)γ, tumor necrosis factor (TNF)α, granulocyte macrophage colony stimulating factor (GM-CSF), and interleukins (IL)-2, IL-8, and IL-10 [98,99]. Xenogeneic models demonstrated that CRS is a supramaximal response of host immune cells rather than CAR T-cells, and demonstrated that the main actor of CRS is IL-6. The main symptoms of CRS are constitutional, such as fever associated with fatigue, myalgia, arthralgia, rigor, and/or anorexia. In some cases, these symptoms could rapidly deteriorate into hypotension, tachycardia, tachypnea, hypoxia, arrhythmia, capillary leak, coagulopathy, respiratory failure, shock, and/or organ dysfunction. The median time to CRS onset varies and depends on the specific CAR T-cell product. For the 4-1BB (CD137) costimulatory domain, the CRS risk peaks at 3 and 7 days after CAR T-cell administration for ALL and DLBCL patients, respectively. In contrast, the onset of CRS symptoms in patients treated with axicabtagene ciloleucel or brexucabtagene autoleucel containing CD28 as a costimulatory domain is earlier, usually 2 days after CAR T-cell administration. However, CRS can occur up to 3 weeks after CAR T-cell administration [102,103,104].
To standardize CRS grading and toxicity management, different multi-institutional scoring systems have been developed. Table 4 reported ASTCT grading [105]. According to these guidelines, the appearance of a fever—defined as a temperature of 38 °C or greater—within 24 h to 3 weeks after CAR T-cell administration is the prerequisite for CRS diagnosis. The grade and severity of CRS is based on hypotension and hypoxia. The administration of tocilizumab, a monoclonal antibody against IL-6, may be considered in patients with CRS grade 2. The early use of tocilizumab reduced the severity of CRS, sparing the function of CAR-T. The combination of corticosteroid may be considered if CRS presents within ICANS and/or the patient presents a deterioration after two doses of tocilizumab.

6.2. Immune-Effector-Cell-Associated Neurotoxicity Syndrome (ICANS)

Neurotoxicity following CAR-T-cell therapy is relatively common and can occur in up to 67% and 62% of leukemia and lymphoma patients, respectively [54]. High-grade ICANS is likely more frequent for CAR-constructs, with CD28 as a costimulatory domain, occurring in up to 45% of treated patients. In contrast, ICANS develops less frequently in patients treated with 4-1BB-containing CAR-T-cells, i.e., tisa-cell, with severe ICANS observed in up to 13% of patients. The pathophysiology of ICANS is less known, and several mechanisms have been identified: passive diffusion of cytokines, endothelial activation, and microglial activation with secretion of cytokines [106]. ICANS management is based on the administration of corticosteroids, but instead, the IL-6 inhibitors are often not effective for neurotoxicity associated with CAR-T-cell therapy [101]. Multiple groups have demonstrated the successful use of the IL-1 antagonist anakinra to ameliorate CRS in mouse models [107]. To date, there are no prophylaxis for the prevention of CAR-T neurotoxicity, so it is mandatory to optimize CAR engineering and develop strategies to decrease CAR-induced ICANS. Table 5 illustrates ASTCT ICANS grading [53,108].

6.3. Hematological Toxicity

In the pivotal studies ZUMA-1 and JULIET, around 31% and 17% of patients, respectively, presented grade ≥ 3 febrile neutropenia. Indeed, 30% of patients treated with axi-cel or tisacel beyond 30 days presented with severe cytopenia [43,109].
CD19-CAR-T presented a biphasic pattern of early and late cytopenia.
Early cytopenia has been attributed to the lymphodepleting chemotherapy, while the etiology of late cytopenia is less clear.
Late cytopenia presents a multifactorial etiology; it may be associated with prior chemotherapy and/or allo-HSCT or a high grade of CRS. The treatment of anemia and thrombocytopenia is based on erythrocytes and platelets transfusions. Granulocyte colony-stimulating factor (G-CSF) can be used to treat prolonged neutropenia. If the cytopenia is persistent, it can be resolved by autologous or allogeneic stem cell supports [110,111].

7. CAR-T-Cell Limitations

Despite its remarkable effectiveness and durable clinical responses, the previous clinical trials in B-cell malignancies demonstrated the limitations of CAR-T-cell therapy, which could be applied in the fields of AML discussed belove. Future studies with a larger number of patients and longer follow-up still must be addressed, which should include life-threatening CAR-T-cell associated toxicity as discussed above, antigen escape, limited persistence, poor trafficking, tumor infiltration, and the immunosuppressive microenvironment. These are discussed below.

7.1. Antigen Escape

One of the biggest challenges of CAR-T-cell therapy is tumor resistance to single-antigen-targeting CAR constructs known as antigen escape. Recent data demonstrated that in about 30–70% of patients, the CD19 antigen was downregulated or completely lost after relapse. Similarly, downregulation or loss of BCMA expression is observed in MM [54,105]. To reduce the relapse rate after CAR-T-cell treatment, several strategies are under investigation based on targeting multiple antigens; among them is the use of dual CAR constructs or tandem CARs. In the first evidence concerning in adult patients with ALL and DLBCL, CD19/CD22 CAR-T has demonstrated promising results, such as in MM regarding the BCMA/CD19-targeted CARs. These data demonstrate the importance of optimizing target antigen selection to improve antitumor response and to decrease antigen escape mechanisms causing relapse [112,113,114,115,116].

7.2. On-Target Off-Tumor Effects

Antigen selection is crucial in CAR design, not only to optimize therapeutic efficacy, but also to limit “on-target off-tumor” toxicity. In hematological malignancies, the use of CAR-T anti-CD19 often results in B-cell aplasia. Further development of innovative strategies to reduce antigen escape, and for selection of antigens with sufficient antitumor activity and minimal toxicity, will be necessary to expand the clinical use of CAR-T-cell therapies in hematological malignancies.

8. Next-Generation CAR-T

As discussed above, current CAR-T-cell therapies approved in USA and Europe are based on second generation constructs, which present two main limitations. The first is their short persistence, which may reduce or nullify treatment efficacy. Pivotal clinical trials using these constructs revealed a relapse rate around 66%. The second aspect is the appearance of life-threatening adverse effects. In recent years, researchers have developed various next-generation CAR-T constructs based on advances in immunology and molecular engineering. Currently, four distinctive approaches are being tested in clinics:
  • Modulation of immune checkpoint pathways (so-called armored CAR-T-cell).
  • Induction of cytokine secretion (defined T-cells redirected for universal cytokine-mediated killing-TRUCKs).
  • Implementation of a safety-switch mechanism to control the treatment-related adverse events.
  • Allogeneic CAR-T (universal CAR-T -UCAR-T-).
The field of CAR-T-cell treatments is very promising, including the use of bispecific second-generation CAR-T-cells that simultaneously target two surface antigens. These studies have had positive results in preclinical and clinical studies with the CAR based on NK cells [117,118].

8.1. Armored CAR-T-Cells

To overcome the inhibition of the tumor microenvironment, different methods have been applied to disrupt the PD1-PDL-1 axis. Liu et al. studied 17 B-cell non-Hodgkin lymphoma patients treated with a CAR-T construct in which the extracellular PD-1 was fused to the intracellular CD28 activating domain, thus transforming the binding of PDL-1 to PD-1 into an activating signal [119]. The results were encouraging, although inferior compared with the rate of complete response of the pivotal studies. Another study disrupted PD-1 signaling by programming CAR-T-cells to secrete PD-1 Fc fusion proteins, preventing its suppressive effects on T-cells. No clinical results have yet been published. The most successful approach seems to be with the use of anbalcabtagene autoleucel (Anbal-cel). This is a novel CAR-T-cell product in which the PD-1 and T-cell immunoreceptors were silenced with Ig and ITIM (immunoreceptor tyrosine-based inhibitory motif) domains previously demonstrated to exhibit significant success in treating B-cell lymphoma [120]. Other approaches used in B-cell non-Hodgkin’s lymphoma include the knockdown PD-1 gene and the incorporation of cytosolic-activated PD-1 by the use of clustered regularly interspaced short palindromic repeats (CRISPR) technology. Armored CAR-T-cells appear to be a valid therapeutic approach in the treatment of both CD19 positive malignancies and myeloid leukemia.

8.2. TRUCK CAR-T

TRUCKs are next-generation CAR-T-cells engineered to express certain cytokines with the aim of improving CAR-T anti-tumor efficacy and persistence, and modulating the tumor microenvironment [112]. An unusual CAR-T construct was developed, incorporating the expression of interleukin-7 (IL-7) and chemokine (C-C Motif) Ligand 19 (CCL19) to mimic the cytokine environment in lymphoid organs. IL-7 promotes the proliferation and survival of T-cells, whereas CCL19 is a chemoattractant for both T-cells and dendritic cells (DCs). IL-7/CCL19-expressing CAR-T-cells were assessed in R/R DLBCL and MM patients, and showed encouraging preliminary results. Interestingly, the TRUCKS approach was also analyzed in patients with Hodgkin’s Lymphoma and cutaneous T-cell lymphoma in which the microenvironment plays a major role. In these settings, anti-CD30 CAR-T incorporating C-C chemokine receptor type 4 (CCR4) showed promising results [121]. These data suggest that TRUCK CAR-T-cells could be another weapon against myeloid leukemia and related diseases, although their efficacy and safety must be confirmed with clinical trials.

8.3. Switchable CAR-T-Cells

Switchable CAR-T-cells have been proposed to control related CRS and neurotoxicity. The rationale behind this approach is to induce apoptosis and complement-dependent cytotoxicity (CDC) and/or ADCC through the administration of an exogenous agent. The mechanism is based on the introduction in the CAR-T of genes encoding surface proteins/antigens or intracellular effectors. When this gene is expressed, CAR-T become responsive to specific drugs and stop their activity. An example of this is the incorporation of truncated epidermal growth factor receptor (EGFRt), into CAR-T-cells. The administration of monoclonal antibody cetuximab may target EGFRt, leading to the elimination of CAR-T reactives via ADCC. The results are still unpublished.

8.4. UCAR-T in AML

Another attractive and innovative option is the use of donor-derived CAR-T-cells, called allogeneic CAR-T, universal CAR-T (UCART), or off-the-shelf CAR-T. The advantages of using a product derived from a healthy donor are multiple. First, UCART is an immediately available product, overcoming the delay of manufacturing autologous CAR-T-cells (three to four weeks), which may be fatal for a highly aggressive disease. Second, the generation of a high number of CAR-T-cells from a single donor decreases overall production costs compared to that of autologous CAR-T-cells. For example, manufacturing UCAR-T-cells produces multiple batches of cryopreserved T-cells, allowing for the possibility of administering several CAR-T doses. Lastly, autologous T-cells may not be effective in some patients due to previous treatments. Despite these positive aspects, UCAR-T-cells present some limitations due to HLA disparities, such as the possibility of inducing graft-versus-host disease (GvHD) and host–mediated rejection. To avoid GvHD, different strategies have been developed. The most explored is genome editing of the T-cell receptor alpha constant domain (TRAC) through transcription activator-like effector nucleases (TALEN) technology [122,123,124]. TALEN has been utilized to disrupt the CD52 gene to reduce rejection. This approach suppresses all CD52+ cells with alemtuzumab, but makes allogeneic CAR-T-cells resistant to lymphodepletion, promoting their persistence. In a phase 1 trial, Sallman and colleagues tested UCART123v1.2, an anti-CD123 allogeneic CAR-T-cell product, in adult patients with relapsed or refractory AML. The results of this study was promising and support the use of UCART123 with fludarabine, cyclophosphamide (FC), and alemtuzumab, a regimen that demonstrated a significantly higher UCART123 cell expansion compared with FC [125].

9. Conclusions

In the past few decades, immunotherapy has emerged as the most effective treatment against solid tumors and hematological malignancies. The success achieved in the treatment of B-cell malignancies using immunotherapeutic approaches is not applicable in AML owing to the absence of a selective antigen on blast cells and the overlap of antigen expression between blasts and normal hematopoietic cells. Studies exploring multiple therapeutic targets are already underway, with promising results in preclinical and clinical studies. In addition, encouraging results in clinical trials on the treatment of AML have been reported, using targets such as CD123, CD33, CLL1, and CD70. The collective efforts of researchers and clinicians for developing novel CARs and applying them in current clinical trials will fulfill the promise to find effective cellular treatments for AML patients. At the same time, research must also be directed towards the development of technologies to limit toxicities and develop more efficient CAR-T constructs.

Author Contributions

M.C., M.M. and P.d.F. wrote the paper. C.M. wrote the bibliography. All authors gave final approval to the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

The authors thank Nathan Tublitz for help in revising the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. De Kouchkovsky, I.; Abdul-Hay, M. Acute myeloid leukemia: A comprehensive review and 2016 update. Blood Cancer J. 2016, 7, e441. [Google Scholar] [CrossRef] [PubMed]
  2. Cornelissen, J.J.; Blaise, D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood J. Am. Soc. Hematol. 2016, 127, 62–70. [Google Scholar] [CrossRef] [PubMed]
  3. Locke, F.L.; Miklos, D.B.; Jacobson, C.A.; Perales, M.A.; Kersten, M.J.; Oluwole, O.O.; Ghobadi, A.; Rapoport, A.P.; McGuirk, J.; Pagel, J.M.; et al. All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N. Engl. J. Med. 2022, 7, 640–654. [Google Scholar] [CrossRef] [PubMed]
  4. Neelapu, S.S.; Locke, F.L.; Bartlett, N.L.; Lekakis, L.J.; Miklos, D.B.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.O.; Siddiqi, T.; Lin, Y.; et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N. Engl. J. Med. 2017, 26, 2531–2544. [Google Scholar] [CrossRef] [PubMed]
  5. Maude, S.L.; Laetsch, T.W.; Buechner, J.; Rives, S.; Boyer, M.; Bittencourt, H.; Bader, P.; Verneris, M.R.; Stefanski, H.E.; Myers, G.D.; et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 2018, 5, 439–448. [Google Scholar] [CrossRef] [PubMed]
  6. Jacobson, C.A.; Chavez, J.C.; Sehgal, A.R.; William, B.M.; Munoz, J.; Salles, G.; Munshi, P.N.; Casulo, C.; Maloney, D.G.; de Vos, S.; et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022, 1, 91–103. [Google Scholar] [CrossRef] [PubMed]
  7. Neelapu, S.S.; Dickinson, M.; Munoz, J.; Ulrickson, M.L.; Thieblemont, C.; Oluwole, O.O.; Herrera, A.F.; Ujjani, C.S.; Lin, Y.; Riedell, P.A.; et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial. Nat. Med. 2022, 28, 735–742. [Google Scholar] [CrossRef] [PubMed]
  8. Shah, B.D.; Ghobadi, A.; Oluwole, O.O.; Logan, A.C.; Boissel, N.; Cassaday, R.D.; Leguay, T.; Bishop, M.R.; Topp, M.S.; Tzachanis, D.; et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 2021, 398, 491–502. [Google Scholar] [CrossRef]
  9. Schuster, S.J.; Bishop, M.R.; Tam, C.S.; Waller, E.K.; Borchmann, P.; McGuirk, J.P.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J.R.; et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2019, 1, 45–56. [Google Scholar] [CrossRef]
  10. Abramson, J.S.; Palomba, M.L.; Gordon, L.I.; Lunning, M.A.; Wang, M.; Arnason, J.; Mehta, A.; Purev, E.; Maloney, D.G.; Andreadis, C.; et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet 2020, 396, 839–852. [Google Scholar] [CrossRef]
  11. Wang, M.; Munoz, J.; Goy, A.; Locke, F.L.; Jacobson, C.A.; Hill, B.T.; Timmerman, J.M.; Holmes, H.; Jaglowski, S.; Flinn, I.W.; et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N. Engl. J. Med. 2020, 14, 1331–1342. [Google Scholar] [CrossRef] [PubMed]
  12. Fowler, N.H.; Dickinson, M.; Dreyling, M.; Martinez-Lopez, J.; Kolstad, A.; Butler, J.; Ghosh, M.; Popplewell, L.; Chavez, J.C.; Bachy, E.; et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial. Nat Med. 2022, 2, 325–332. [Google Scholar] [CrossRef] [PubMed]
  13. San-Miguel, J.; Dhakal, B.; Yong, K.; Spencer, A.; Anguille, S.; Mateos, M.V.; Fernández de Larrea, C.; Martínez-López, J.; Moreau, P.; Touzeau, C.; et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N. Engl. J. Med. 2023, 4, 335–347. [Google Scholar] [CrossRef] [PubMed]
  14. Cheadle, E.J.; Gornall, H.; Baldan, V.; Hanson, V.; Hawkins, R.E.; Gilham, D.E. CAR T cells: Driving the road from the laboratory to the clinic. Immunol. Rev. 2013, 257, 91–106. [Google Scholar] [CrossRef]
  15. Bezverbnaya, K.; Mathews, A.; Sidhu, J.; Helsen, C.W.; Bramson, J.L. Tumor-targeting domains for chimeric antigen receptor T cells. Immunotherapy 2017, 1, 33–46. [Google Scholar] [CrossRef] [PubMed]
  16. Safarzadeh Kozani, P.; Naseri, A.; Mirarefin, S.M.J.; Salem, F.; Nikbakht, M.; Evazi Bakhshi, S.; Safarzadeh Kozani, P. Nanobody-based CAR-T cells for cancer immunotherapy. Biomark. Res. 2022, 1, 24. [Google Scholar] [CrossRef] [PubMed]
  17. Bridgeman, J.S.; Hawkins, R.E.; Bagley, S.; Blaylock, M.; Holland, M.; Gilham, D.E. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J. Immunol. 2010, 12, 6938–6949. [Google Scholar] [CrossRef]
  18. Dotti, G.; Gottschalk, S.; Savoldo, B.; Brenner, M.K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 2014, 1, 107–126. [Google Scholar] [CrossRef]
  19. Alabanza, L.; Pegues, M.; Geldres, C.; Shi, V.; Wiltzius, J.J.W.; Sievers, S.A.; Yang, S.; Kochenderfer, J.N. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions is Affected by Hinge and Transmembrane Domains. Mol. Ther. 2017, 11, 2452–2465. [Google Scholar] [CrossRef]
  20. Brocker, T.; Karjalainen, K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J. Exp. Med. 1995, 181, 1653–1659. [Google Scholar] [CrossRef]
  21. Brentjens, R.J.; Latouche, J.B.; Santos, E.; Marti, F.; Gong, M.C.; Lyddane, C.; King, P.D.; Larson, S.; Weiss, M.; Rivière, I.; et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 2003, 9, 279–286. [Google Scholar] [CrossRef] [PubMed]
  22. Mata, M.; Gerken, C.; Nguyen, P.; Krenciute, G.; Spencer, D.M.; Gottschalk, S. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models. Cancer Discov. 2017, 11, 1306–1319. [Google Scholar] [CrossRef] [PubMed]
  23. Hombach, A.A.; Heiders, J.; Foppe, M.; Chmielewski, M.; Abken, H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 2012, 4, 458–466. [Google Scholar] [CrossRef] [PubMed]
  24. Zhang, C.; Liu, J.; Zhong, J.F.; Zhang, X. Engineering CAR-T cells. Biomark. Res. 2017, 24, 22. [Google Scholar] [CrossRef] [PubMed]
  25. Van der Stegen, S.J.; Hamieh, M.; Sadelain, M. The pharmacology of second generation chimeric antigen receptors. Nat. Rev. Drug Discov. 2015, 7, 499–509. [Google Scholar] [CrossRef]
  26. Acuto, O.; Michel, F. CD28-mediated co-stimulation: A quantitative support for TCR signalling. Nat. Rev. Immunol. 2003, 12, 939–951. [Google Scholar] [CrossRef]
  27. Smith, A.J.; Oertle, J.; Warren, D.; Prato, D. Chimeric antigen receptor (Car) T cell therapy for malignant cancers: Summary and perspective. J. Cell. Immunother. 2016, 2, 59–68. [Google Scholar] [CrossRef]
  28. Martínez-Lostao, L.; Anel, A.; Pardo, J. How Do Cytotoxic Lymphocytes Kill Cancer Cells? Clin. Cancer Res. 2015, 22, 5047–5056. [Google Scholar] [CrossRef]
  29. Enblad, G.; Karlsson, H.; Loskog, A.S. CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma. Hum. Gene Ther. 2015, 8, 498–505. [Google Scholar] [CrossRef]
  30. Kagoya, Y.; Tanaka, S.; Guo, T.; Anczurowski, M.; Wang, C.H.; Saso, K.; Butler, M.O.; Minden, D.; Hirano, N. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat. Med. 2018, 3, 352–359. [Google Scholar] [CrossRef]
  31. Taussig, D.C.; Pearce, D.J.; Simpson, C.; Rohatiner, A.Z.; Lister, T.A.; Kelly, G.; Luongo, J.L.; Danet-Desnoyers, G.A.; Bonnet, D. Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005, 13, 4086–4092. [Google Scholar] [CrossRef] [PubMed]
  32. Fiorenza, S.; Turtle, C.J. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success. BioDrugs 2021, 35, 281–302. [Google Scholar] [CrossRef] [PubMed]
  33. Wang, Q.S.; Wang, Y.; Lv, H.Y.; Han, Q.W.; Fan, H.; Guo, B.; Wang, L.-L.; Han, W.-D. Treatment of Cd33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther. 2015, 23, 184–191. [Google Scholar] [CrossRef] [PubMed]
  34. Tang, X.; Yang, L.; Li, Z.; Nalin, A.P.; Dai, H.; Xu, T.; Yin, J.; You, F.; Zhu, M.; Shen, W.; et al. First-in man clinical trial of CAR NK-92 cells: Safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am. J. Cancer Res. 2018, 8, 1083–1089. [Google Scholar] [PubMed]
  35. Budde, L.E. Chimeric antigen receptor T-cell therapy acute myeloid leukemia: Targeting CD123. In 1st European CAR T Cell Meeting Report; European Haematology Association: Paris, France, 2019. [Google Scholar]
  36. Bu, C.; Peng, Z.; Luo, M.; Guangchao, L.; Chunfu, L. Phase I clinical trial of autologous CLL1 CAR-T therapy for pediatric patients with relapsed and refractory acute myeloid leukemia. In Proceedings of the 62nd Annual ASH Meeting, Virtual, 5–8 December 2020; American Society of Hematology: Washington, DC, USA, 2020. [Google Scholar]
  37. Barber, A.; Meehan, K.R.; Sentman, C.L. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther. 2011, 18, 509–516. [Google Scholar] [CrossRef] [PubMed]
  38. Baumeister, S.H.; Murad, J.; Werner, L.; Daley, H.; Trebeden-Negre, H.; Gicobi, J.K.; Schmucker, A.; Reder, J.; Sentman, C.L.; Gilham, D.E.; et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. Cancer Immunol. Res. 2019, 7, 100–112. [Google Scholar] [CrossRef]
  39. Sugiyama, H. WT1 (Wilms’ Tumor Gene 1): Biology and Cancer Immunotherapy. Jpn. J. Clin. Oncol. 2010, 5, 377–387. [Google Scholar] [CrossRef]
  40. Minagawa, K.; Jamil, M.O.; Al-Obaidi, M.; Pereboeva, L.; Salzman, D.; Erba, H.P.; Lamb, L.S.; Bhatia, R.; Mineishi, S.; Di Stasi, A. In vitro pre-clinical validation of suicide gene modified anti-Cd33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia. PLoS ONE 2016, 11, e0166891. [Google Scholar] [CrossRef]
  41. Riether, C.; Schürch, C.M.; Bührer, E.D.; Hinterbrandner, M.; Huguenin, A.L.; Hoepner, S.; Zlobec, I.; Pabst, T.; Radpour, R.; Ochsenbein, A.F. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J. Exp. Med. 2017, 2, 359–380. [Google Scholar] [CrossRef]
  42. Campana, D.; Coustan-Smith, E. Minimal Residual Disease Studies by Flow Cytometry in Acute Leukemia. Acta Haematol. 2004, 112, 8–15. [Google Scholar] [CrossRef]
  43. Hill, J.A.; Li, D.; Hay, K.A.; Green, M.L.; Cherian, S.; Chen, X.; Riddell, S.R.; Maloney, D.G.; Boeckh, M.; Turtle, C.J. Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy. Blood 2018, 131, 121–130. [Google Scholar] [CrossRef] [PubMed]
  44. El Achi, H.; Dupont, E.; Paul, S.; Khoury, J.D. CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. Cancers 2020, 11, 3087. [Google Scholar] [CrossRef] [PubMed]
  45. Qin, H.; Edwards, J.P.; Zaritskaya, L.; Gupta, A.; Mu, C.J.; Fry, T.J.; Hilbert, D.M.; LaFleur, D.W. Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells. Mol. Ther. 2019, 7, 1262–1274. [Google Scholar] [CrossRef] [PubMed]
  46. Liu, F.; Cao, Y.; Pinz, K.; Ma, Y.; Wada, M.; Chen, K.; Ma, G.; Shen, J.; Tse, C.O.; Su, Y.; et al. First-in-Human Cll1- Cd33 compound car T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: Update on phase 1 clinical trial. Blood 2018, 132 (Suppl. S1), 901. [Google Scholar] [CrossRef]
  47. Lynn, R.C.; Poussin, M.; Kalota, A.; Feng, Y.; Low, P.S.; Dimitrov, D.S.; Powell, D.J., Jr. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor–expressing T cells. Blood 2015, 22, 3466–3476. [Google Scholar] [CrossRef] [PubMed]
  48. Rafiq, S.; Purdon, T.J.; Daniyan, A.F.; Koneru, M.; Dao, T.; Liu, C.; Scheinberg, D.A.; Brentjens, R.J. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia 2017, 8, 1788–1797. [Google Scholar] [CrossRef] [PubMed]
  49. Patel, N.; Brinkman-Van der Linden, E.C.; Altmann, S.W.; Gish, K.; Balasubramanian, S.; Timans, J.C.; Peterson, D.; Bell, M.P.; Bazan, J.F.; Varki, A.; et al. OB-BP1/Siglec-6. a leptin- and sialic acid-binding protein of the immunoglobulin super-family. J. Biol. Chem. 1999, 32, 22729–22738. [Google Scholar] [CrossRef]
  50. Coustan-Smith, E.; Song, G.; Shurtleff, S.; Yeoh, A.E.-J.; Chng, W.J.; Chen, S.P.; Rubnitz, J.E.; Pui, C.-H.; Downing, J.R.; Campana, D. Universal monitoring of minimal residual disease in acute myeloid leukemia. J. Clin. Investig. 2018, 3, 98561. [Google Scholar] [CrossRef]
  51. Wang, J.; Chen, S.; Xiao, W.; Li, W.; Wang, L.; Yang, S.; Wang, W.; Xu, L.; Liao, S.; Liu, W.; et al. Car-T cells targeting cll-1 as an approach to treat acute myeloid leukemia. J. Hematol. Oncol. 2018, 11, 7. [Google Scholar] [CrossRef]
  52. Leick, M.B.; Silva, H.; Scarfò, I.; Larson, R.; Choi, B.D.; Bouffard, A.A.; Gallagher, K.; Schmidts, A.; Bailey, S.R.; Kann, M.C.; et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 2022, 5, 494–508. [Google Scholar] [CrossRef]
  53. Santomasso, B.D.; Park, J.H.; Salloum, D.; Riviere, I.; Flynn, J.; Mead, E.; Halton, E.; Wang, X.; Senechal, B.; Purdon, T.; et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2018, 8, 958–971. [Google Scholar] [CrossRef]
  54. Titov, A.; Petukhov, A.; Staliarova, A.; Motorin, D.; Bulatov, E.; Shuvalov, O.; Soond, S.M.; Piacentini, M.; Melino, G.; Zaritskey, A.; et al. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. Cell Death Dis. 2018, 9, 897. [Google Scholar] [CrossRef] [PubMed]
  55. Nguyen, D.H.; Ball, E.D.; Varki, A. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs. Exp. Hematol. 2006, 34, 728–735. [Google Scholar] [CrossRef] [PubMed]
  56. Kenderian, S.S.; Ruella, M.; Shestova, O.; Klichinsky, M.; Aikawa, V.; Morrissette, J.J.; Scholler, J.; Song, D.; Porter, D.L.; Carroll, M.; et al. Cd33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 2015, 29, 1637–1647. [Google Scholar] [CrossRef] [PubMed]
  57. Li, S.; Tao, Z.; Xu, Y.; Liu, J.; An, N.; Wang, Y.; Xing, H.; Tian, Z.; Tang, K.; Liao, X.; et al. Cd33-specific chimeric antigen receptor T cells with different Co-stimulators showed potent anti-leukemia efficacy and different phenotype. Hum. Gene Ther. 2018, 29, 626–639. [Google Scholar] [CrossRef] [PubMed]
  58. Zheng, W.; O’Hear, C.E.; Alli, R.; Basham, J.H.; Abdelsamed, H.A.; Palmer, L.E.; Jones, L.L.; Youngblood, B.; Geiger, T.L. Pi3k orchestration of the in vivo persistence of chimeric antigen receptor modified T cells. Leukemia 2018, 32, 1157–1167. [Google Scholar] [CrossRef] [PubMed]
  59. Tambaro, F.P.; Singh, H.; Jones, E.; Rytting, M.; Mahadeo, K.M.; Thompson, P.; Daver, N.; DiNardo, C.; Kadia, T.; Garcia-Manero, G.; et al. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 2021, 11, 3282–3286. [Google Scholar] [CrossRef]
  60. Liu, Y.; Wang, S.; Schubert, M.L.; Lauk, A.; Yao, H.; Blank, M.F.; Cui, C.; Janssen, M.; Schmidt, C.; Göllner, S.; et al. Cd33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and Cd33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int. J. Cancer 2021, 150, 1141–1155. [Google Scholar] [CrossRef]
  61. Yao, S.; Jianlin, C.; Yarong, L.; Botao, L.; Qinghan, W.; Hongliang, F.; Lu, Z.; Hongmei, N.; Pin, W.; Hu, C.; et al. Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient with FUS-ERG+ AML. Front. Oncol. 2019, 3, 1358. [Google Scholar] [CrossRef]
  62. You, L.; Han, Q.; Zhu, L.; Zhu, Y.; Bao, C.; Yang, C.; Lei, W.; Qian, W. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells. Front. Immunol. 2020, 18, 1787. [Google Scholar] [CrossRef]
  63. Testa, U.; Pelosi, E.; Frankel, A. Cd 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark. Res. 2014, 2, 4. [Google Scholar] [CrossRef] [PubMed]
  64. Testa, U.; Riccioni, R.; Militi, S.; Coccia, E.; Stellacci, E.; Samoggia, P.; Latagliata, R.; Mariani, G.; Rossini, A.; Battistini, A.; et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 2002, 8, 2980–2988. [Google Scholar] [CrossRef] [PubMed]
  65. Gill, S.; Tasian, S.K.; Ruella, M.; Shestova, O.; Li, Y.; Porter, D.L.; Carroll, M.; Danet-Desnoyers, G.; Scholler, J.; Grupp, S.A.; et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014, 15, 2343–2354. [Google Scholar] [CrossRef] [PubMed]
  66. Jiang, G.; Atenafu, E.G.; Capo-Chichi, J.M.; Minden, M.D.; Chang, H. Prognostic relevance of CD123 expression in adult AML with normal karyotype. Br. J. Haematol. 2020, 1, 181–184. [Google Scholar] [CrossRef] [PubMed]
  67. Luo, Y.; Chang, L.J.; Hu, Y.; Dong, L.; Wei, G.; Huang, H. First-in-Man Cd123-specific chimeric antigen receptor-modified T cells for the treatment of refractory acute myeloid leukemia. Blood 2015, 126, 3778. [Google Scholar] [CrossRef]
  68. Tasian, S.K.; Kenderian, S.S.; Shen, F.; Ruella, M.; Shestova, O.; Kozlowski, M.; Li, Y.; Schrank-Hacker, A.; Morrissette, J.J.D.; Carroll, M.; et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood 2017, 17, 2395–2407. [Google Scholar] [CrossRef]
  69. Arcangeli, S.; Rotiroti, M.C.; Bardelli, M.; Simonelli, L.; Magnani, C.F.; Biondi, A.; Biagi, E.; Tettamanti, S.; Varani, L. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia. Mol. Ther. 2017, 8, 1933–1945. [Google Scholar] [CrossRef]
  70. Van Rhenen, A.; van Dongen, G.A.; Kelder, A.; Rombouts, E.J.; Feller, N.; Moshaver, B.; Stigter-van Walsum, M.; Zweegman, S.; Ossenkoppele, G.J.; Jan Schuurhuis, G. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007, 7, 2659–2666. [Google Scholar] [CrossRef]
  71. Zhao, X.; Singh, S.; Pardoux, C.; Zhao, J.; His, E.D.; Abo, A.; Korver, W. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 2010, 1, 71–78. [Google Scholar] [CrossRef]
  72. Tashiro, H.; Sauer, T.; Shum, T.; Parikh, K.; Mamonkin, M.; Omer, B.; Rouce, R.H.; Lulla, P.; Rooney, C.M.; Gottschalk, S.; et al. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol. Ther. 2017, 9, 2202–2213. [Google Scholar] [CrossRef]
  73. Atilla, P.A.; Atilla, E.; Tashiro, H.; Srinivasan, M.; Silva, D.G.; Mamonkin, M.; Brenner, M.K. Optimizing c-type lectin-like molecule 1 (Cll-1) directed car T cell therapy of acute myeloid leukemia. Biol. Blood Marrow Transpl. 2019, 25, S167–S168. [Google Scholar] [CrossRef]
  74. Lin, G.; Zhang, Y.; Yu, L.; Wu, D. Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed/refractory acute myeloid leukemia. Mol. Med. Rep. 2021, 3, 208. [Google Scholar] [CrossRef] [PubMed]
  75. Jin, X.; Zhang, M.; Sun, R.; Lyu, H.; Xiao, X.; Zhang, X.; Li, F.; Xie, D.; Xiong, X.; Wang, J.; et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. J. Hematol. Oncol. 2022, 1, 88. [Google Scholar] [CrossRef] [PubMed]
  76. Shaffer, D.R.; Savoldo, B.; Yi, Z.; Chow, K.K.; Kakarla, S.; Spencer, D.M.; Dotti, G.; Wu, M.F.; Liu, H.; Kenney, S.; et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 2011, 117, 4304–4314. [Google Scholar] [CrossRef] [PubMed]
  77. Nolte, M.A.; van Olffen, R.W.; van Gisbergen, K.P.; van Lier, R.A. Timing and tuning of CD27-CD70 interactions: The impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev. 2009, 1, 216–231. [Google Scholar] [CrossRef] [PubMed]
  78. Riether, C.; Pabst, T.; Höpner, S.; Bacher, U.; Hinterbrandner, M.; Banz, Y.; Müller, R.; Manz, M.G.; Gharib, W.H.; Francisco, D.; et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat. Med. 2020, 26, 1459–1467. [Google Scholar] [CrossRef] [PubMed]
  79. Sauer, T.; Parikh, K.; Sharma, S.; Omer, B.; Sedloev, D.; Chen, Q.; Angenendt, L.; Schliemann, C.; Schmitt, M.; Müller-Tidow, C.; et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood 2021, 4, 318–330. [Google Scholar] [CrossRef] [PubMed]
  80. Wu, G.; Guo, S.; Luo, Q.; Wang, X.; Deng, W.; Ouyang, G.; Pu, J.J.; Lei, W.; Qian, W. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. Front. Immunol. 2023, 14, 1093750. [Google Scholar] [CrossRef]
  81. Garrity, D.; Call, M.E.; Fen, J.; Wucherpfennig, K.W. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc. Natl. Acad. Sci. USA 2005, 102, 7641–7646. [Google Scholar] [CrossRef]
  82. Lanier, L.L. NKG2D receptor and its ligands in host defense. Cancer Immunol. Res. 2015, 3, 575–582. [Google Scholar] [CrossRef]
  83. Deeren, D.; Maertens, J.; Lin, T.; Beguin, Y.; Demoulin, B.; Fontaine, M.; Sotiropoulou, P.A.; Alcantar-Orozco, E.; Breman, E.; Dheur, M.-S.; et al. First results from the dose escalation segment of the phase I clinical study evaluating Cyad-02, an optimized non gene-edited engineered NKG2D CAR T-cell product, in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients. In Proceedings of the 62nd Annual ASH Meeting, Virtual, 5–8 December 2020; American Society of Hematology: Washington, DC, USA, 2020. [Google Scholar]
  84. Kottaridis, P.D.; Gale, R.E.; Frew, M.E.; Harrison, G.; Langabeer, S.E.; Belton, A.A.; Walker, H.; Wheatley, K.; Bowen, D.T.; Burnett, A.K.; et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 6, 1752–1759. [Google Scholar]
  85. Gilliland, D.G.; Griffin, J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 5, 1532–1542. [Google Scholar] [CrossRef] [PubMed]
  86. Yamamoto, Y.; Kiyoi, H.; Nakano, Y.; Suzuki, R.; Kodera, Y.; Miyawaki, S.; Asou, N.; Kuriyama, K.; Yagasaki, F.; Shimazaki, C.; et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 8, 2434–2439. [Google Scholar] [CrossRef] [PubMed]
  87. Chien, C.D.; Sauter, C.T.; Ishii, K.; Nguyen, S.M.; Shen, F.; Tasian, S.K.; Chen, W.; Dimitrov, D.S.; Fry, T.J. Preclinical development of FLT3-redirected chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia. Am. Soc. Hematol. 2016, 128, 1072. [Google Scholar] [CrossRef]
  88. Wang, Y.; Xu, Y.; Li, S.; Liu, J.; Xing, Y.; Xing, H.; Tian, Z.; Tang, K.; Rao, Q.; Wang, M.; et al. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells. J. Hematol. Oncol. 2018, 1, 60. [Google Scholar] [CrossRef]
  89. Saxena, A.; Sheridan, D.P.; Card, R.T.; McPeek, A.M.; Mewdell, C.C.; Skinnider, L.F. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am. J. Hematol. 1998, 4, 278–284. [Google Scholar] [CrossRef]
  90. Gomes-Silva, D.; Srinivasan, M.; Sharma, S.; Lee, C.M.; Wagner, D.L.; Davis, T.H.; Rouce, R.H.; Bao, G.; Brenner, M.K.; Mamonkin, M. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 2017, 130, 285–296. [Google Scholar] [CrossRef]
  91. Ross, J.F.; Wang, H.; Behm, F.G.; Mathew, P.; Wu, M.; Booth, R.; Ratnam, M. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999, 2, 348–357. [Google Scholar] [CrossRef]
  92. Molldrem, J.J.; Lee, P.P.; Wang, C.; Felio, K.; Kantarjian, H.M.; Champlin, R.E.; Davis, M.M. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 2000, 6, 1018–1023. [Google Scholar] [CrossRef]
  93. Ma, Q.; Garber, H.R.; Lu, S.; He, H.; Tallis, E.; Ding, X.; Sergeeva, A.; Wood, M.S.; Dotti, G.; Salvado, B.; et al. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cyto-therapy 2016, 8, 985–994. [Google Scholar] [CrossRef]
  94. Di Stasi, A.; Jimenez, A.M.; Eminagawa, K.; Eal-Obaidi, M.; Erezvani, K. Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies. Front. Immunol. 2015, 6, 36. [Google Scholar] [CrossRef] [PubMed]
  95. Morrison, A.A.; Viney, R.L.; Ladomery, M.R. The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim. Biophys. Acta 2008, 1, 55–62. [Google Scholar] [CrossRef] [PubMed]
  96. John, S.; Chen, H.; Deng, M.; Gui, X.; Wu, G.; Chen, W.; Li, Z.; Zhang, N.; An, Z.; Zhang, C.C. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. Mol. Ther. 2018, 26, 2487–2495. [Google Scholar] [CrossRef] [PubMed]
  97. Pérez-Amill, L.; Armand-Ugon, M.; Peña, S.; Val Casals, M.; Santos, C.; Frigola, G.; Minguela, A.; Bataller Torralba, A.; Casanovas, B.; Álamo, J.; et al. CD84: A Novel Target for CAR T-Cell Therapy for Acute Myeloid Leukemia. Blood 2022, 140 (Suppl. S1), 7379–7381. [Google Scholar] [CrossRef]
  98. Jetani, H.; Navarro-Bailón, A.; Maucher, M.; Frenz, S.; Verbruggen, C.; Yeguas, A.; Vidriales, M.B.; González, M.; Saborido, J.R.; Kraus, S.; et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood 2021, 138, 1830–1842. [Google Scholar] [CrossRef] [PubMed]
  99. Koyama, S.; Akbay, E.A.; Li, Y.Y.; Herter-Sprie, G.S.; Buczkowski, K.A.; Richards, W.G.; Gandhi, L.; Redig, A.J.; Rodig, S.J.; Asahina, H.; et al. Adaptive re-sistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 2016, 7, 10501. [Google Scholar] [CrossRef]
  100. He, X.; Feng, Z.; Ma, J.; Ling, S.; Cao, Y.; Gurung, B.; Wu, Y.; Katona, B.W.; O’Dwyer, K.P.; Siegel, D.L.; et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood 2020, 135, 713–723. [Google Scholar] [CrossRef]
  101. Richards, R.M.; Zhao, F.; Freitas, K.A.; Parker, K.R.; Xu, P.; Fan, A.; Sotillo, E.; Daugaard, M.; Oo, H.Z.; Liu, J.; et al. NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. Blood Cancer Discov. 2021, 2, 648–665. [Google Scholar] [CrossRef]
  102. Norelli, M.; Camisa, B.; Barbiera, G.; Falcone, L.; Purevdorj, A.; Genua, M.; Sanvito, F.; Ponzoni, M.; Doglioni, C.; Cristofori, P.; et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 2018, 24, 739–748. [Google Scholar] [CrossRef]
  103. Giavridis, T.; van der Stegen, S.J.C.; Eyquem, J.; Hamieh, M.; Piersigilli, A.; Sadelain, M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 2018, 24, 731–738. [Google Scholar] [CrossRef]
  104. Morris, E.C.; Neelapu, S.S.; Giavridis, T.; Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer im-munotherapy. Nat. Rev. Immunol. 2022, 22, 85–96. [Google Scholar] [CrossRef] [PubMed]
  105. Lee, D.W.; Santomasso, B.D.; Locke, F.L.; Ghobadi, A.; Turtle, C.J.; Brudno, J.N.; Maus, M.V.; Park, J.H.; Mead, E.; Pavletic, S.; et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol. Blood Marrow Transplant. 2019, 25, 625–638. [Google Scholar] [CrossRef] [PubMed]
  106. Sachdeva, M.; Duchateau, P.; Depil, S.; Poirot, L.; Valton, J. Granulocyte–macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J. Biol. Chem. 2019, 14, 5430–5437. [Google Scholar] [CrossRef] [PubMed]
  107. Neelapu, S.S.; Tummala, S.; Kebriaei, P.; Wierda, W.; Gutierrez, C.; Locke, F.L.; Komanduri, K.V.; Lin, Y.; Jain, N.; Daver, N.; et al. Chimeric antigen receptor T-cell therapy—Assessment and management of toxicities. Nat. Rev. Clin. Oncol. 2017, 15, 47–62. [Google Scholar] [CrossRef]
  108. Lee, D.W.; Gardner, R.; Porter, D.L.; Louis, C.U.; Ahmed, N.; Jensen, M.; Grupp, S.A.; Mackall, C.L. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014, 124, 188–195. [Google Scholar] [CrossRef]
  109. Fried, S.; Avigdor, A.; Bielorai, B.; Meir, A.; Besser, M.J.; Schachter, J.; Shimoni, A.; Nagler, A.; Toren, A.; Jacoby, E. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019, 10, 1643–1650. [Google Scholar] [CrossRef]
  110. Lin, Q.; Liu, X.; Han, L.; Liu, L.; Fang, B.; Gao, Q.; Song, Y. Autologous hematopoietic stem cell infusion for sustained myelo-suppression after BCMA-CAR-T therapy in patient with relapsed myeloma. Bone Marrow Transplant. 2020, 6, 1203–1205. [Google Scholar] [CrossRef]
  111. Schubert, M.-L.; Dietrich, S.; Stilgenbauer, S.; Schmitt, A.; Pavel, P.; Kunz, A.; Bondong, A.; Wegner, M.; Stadtherr, P.; Jung, S.; et al. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol. Blood Marrow Transplant. 2020, 9, 1575–1580. [Google Scholar] [CrossRef]
  112. Majzner, R.G.; Mackall, C.L. Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018, 8, 1219–1226. [Google Scholar] [CrossRef]
  113. Maude, S.L.; Teachey, D.T.; Porter, D.L.; Grupp, S.A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lym-phoblastic leukemia. Blood 2015, 125, 4017–4023. [Google Scholar] [CrossRef]
  114. Green, D.J.; Pont, M.; Sather, B.D.; Cowan, A.J.; Turtle, C.J.; Till, B.G.; Nagengast, A.M.; Libby, E.N.; Becker, P.S.; Coffey, D.G.; et al. Fully human bcma targeted chimeric antigen receptor T cells administered in a defined composition demon-strate potency at low doses in advanced stage high risk multiple myeloma. Blood 2018, 132, 1011. [Google Scholar] [CrossRef]
  115. Brudno, J.N.; Maric, I.; Hartman, S.D.; Rose, J.J.; Wang, M.; Lam, N.; Stetler-Stevenson, M.; Salem, D.; Yuan, C.; Pavletic, S.; et al. T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. J. Clin. Oncol. 2018, 22, 2267–2280. [Google Scholar] [CrossRef] [PubMed]
  116. Cohen, A.D.; Garfall, A.L.; Stadtmauer, E.A.; Melenhorst, J.J.; Lacey, S.F.; Lancaster, E.; Vogl, D.T.; Weiss, B.M.; Dengel, K.; Nelson, A.; et al. B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma. J. Clin. Investig. 2019, 6, 2210–2221. [Google Scholar] [CrossRef] [PubMed]
  117. Spiegel, J.Y.; Patel, S.; Muffly, L.; Hossain, N.M.; Oak, J.; Baird, J.H.; Frank, M.J.; Shiraz, P.; Sahaf, B.; Craig, J.; et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: A phase 1 trial. Nat. Med. 2021, 8, 1419–1431. [Google Scholar] [CrossRef] [PubMed]
  118. Cordoba, S.; Onuoha, S.; Thomas, S.; Pignataro, D.S.; Hough, R.; Ghorashian, S.; Vora, A.; Bonney, D.; Veys, P.; Rao, K.; et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: A phase 1 trial. Nat. Med. 2021, 27, 1797–1805. [Google Scholar] [CrossRef]
  119. Liu, H.; Lei, W.; Zhang, C.; Yang, C.; Wei, J.; Guo, Q. CD19-specific CAR T cells that express a PD-1/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive b-cell lymphoma. Clin. Cancer Res. 2021, 27, 473–484. [Google Scholar] [CrossRef]
  120. Kim, W.S.; Kim, S.J.; Yoon, S.; Kim, J.R. Phase 1/2 study of anbalcabtagene autoleucel, novel anti-CD19 CAR-T cell therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma. J. Clin. Oncol. 2022, 40, 7522. [Google Scholar] [CrossRef]
  121. Rafiq, S.; Hackett, C.S.; Brentjens, R.J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 2020, 17, 147–167. [Google Scholar] [CrossRef]
  122. Depil, S.; Duchateau, P.; Grupp, S.A.; Mufti, G.; Poirot, L. ‘Off-the-shelf’ allogeneic CAR T cells: Development and challenges. Nat. Rev. Drug Discov. 2020, 19, 185–199. [Google Scholar] [CrossRef]
  123. Poirot, L.; Philip, B.; Schiffer-Mannioui, C.; Le Clerre, D.; Chion-Sotinel, I.; Derniame, S.; Potrel, P.; Bas, C.; Lemaire, L.; Galetto, R.; et al. Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies. Cancer Res. 2015, 75, 3853–3864. [Google Scholar] [CrossRef]
  124. Berdien, B.; Mock, U.; Atanackovic, D.; Fehse, B. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 2014, 21, 539–548. [Google Scholar] [CrossRef] [PubMed]
  125. Sallman, D.A.; DeAngelo, D.J.; Pemmaraju, N.; Dinner, S.; Gill, S.; Olin, R.; Wang, E.; Konopleva, M.; Stark, E.; Kongold, K.; et al. AMELI-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML). Blood 2022, 140 (Suppl. S1), 2371–2373. [Google Scholar] [CrossRef]
Cancers 16 00042 g002
Figure 2. Five generations of CAR-T.
Figure 2. Five generations of CAR-T.
Cancers 16 00042 g002
Table 1. Currently clinical trials open to recruitment.
Table 1. Currently clinical trials open to recruitment.
Target AntigenClinical Trial IDPhaseDisease StatusIntervetionInstitution
CD33NCT05672147Phase IAML R/RCD33 CAR-TCity of Hope Medical Cente
NCT05248685Phase IAML R/RCD33/CLL1 CAR-TBeijing Boren Hospital
NCT04835519Phase I/IIAML R/RCD33 CAR-TBeijing Boren Hospital
NCT04010877Phase I/IIAML R/RUCARTCD33 CLL-1, CD33, CD38 and CD123Shenzhen Geno-Immune Medical Institute
NCT03971799Phase I/IIAML R/RCD33 CAR-TCenter for International Blood and Marrow Transplant Research
NCT05105152Phase IAML R/RCD33 CAR-TSeattle Children’s Hospital
CD123NCT04265963Phase IAML R/RCD123 CAR-TChongqing Precision Biotech Co., Ltd.
NCT04272125Phase IAML R/RCD123 CAR-TChongqing Precision Biotech Co., Ltd.
NCT04010877Phase IAML R/RCAR-T CLL-1, CD33 and/or CD123Shenzhen Geno-Immune Medical Institute
NCT05457010Phase IAML R/RSPRX002 and ARC TArcellx, Inc.
NCT04230265Phase IAML R/R and BPDCNUniCAR02-TAvenCell Europe GmbH
NCT06125652Phase I/IIAML R/Ranti Tim3/CD123Xuzhou Medical University
CLL1NCT04923919Early Phase 1AML R/RCLL1 CAR-T920th Hospital of Joint Logistics Support Force of People’s Liberation Army of China
NCT05248685Phase 1AML R/RDual CD33/CLL1 CAR-TBeijing Boren Hospital
NCT04219163Phase 1AML R/RCLL1 CAR-TBaylor College of Medicine
NCT04884984Phase 1/2AML R/RCLL1 CAR-TThe First Affiliated Hospital of Soochow University
NCT04010877Phase 1/2AML R/RCLL1 CAR-TShenzhen Geno-Immune Medical Institute
NCT06017258Phase 1AML R/RCD371-YSNVZ-IL18 CAR-TMemorial Sloan Kettering Cancer Center (Responsible Party)
NCT04789408Phase 1AML R/RCLL-1 CAR TKite, A Gilead Company
NCT06110208Early Phase 1AML R/RCLL1 and CD38 dual-target CAR-T injection920th Hospital of Joint Logistics Support Force of People’s Liberation Army of China
CD70NCT04662294Early Phase 1Non-Hodgkin’s Lymphoma Multiple Myeloma AML R/RCD70 CAR-TZhejiang University
FLT3NCT05023707Phase 1/2R/R AMLAnti-Flt3 CAR-TThe First Affiliated Hospital of Soochow University
NCT05445011Phase 1R/R AMLAnti-Flt3 CAR-TWuhan Union Hospital, China
CD7NCT04762485Phase 1/2R/R AML
R/R T ALL		Anti-CD7 CAR-TThe First Affiliated Hospital of Soochow University
NCT04033302Phase 1/2R/R AML
R/R T ALL		Anti-CD7 CAR-TShenzhen Geno-Immune Medical Institute
NCT05907603Early Phase 1R/R AML
R/R T ALL		RD13-02 cell infusionKai Lin Xu, MD
Table 2. Results of main AML CAR-T clinical trials published.
Table 2. Results of main AML CAR-T clinical trials published.
AntigensPts (nr)Lymphodepletation RegimenBest ResponceSide Effects (Grade)Ref
CRSICANSOTHER
CD331NA1 PRgrade 2-Aplasia[33]
31 ARA-C 2 g/m2+
MTZ 8 g/m2/day
1 Flu30 mg/m2+
ARA-C 1 g/m2
1 ARA-C 1.5
gr/m2 + MTZ 10 mg/m2		1 CR
2 PD		2 pts
grade 2		 3 pts
Sepsis		[34]
CD1237Flu and Cy1 CR i
2CR
1MLFS
1PD
2 SD		8 pts grade 1–34 pts grade 1–33 sepsis
9 aplasia		[35]
CLL-13NA3 CR
7 no response		2 pts
grade 1–3		[36]
NKG2D7NA7 no responseNA[37]
2Flu 30 mg/m2 +
Cy 300 mg/m2		1 SD
1 no response		2 pts grade 3[38]
Abbreviations: PTs patients; nr numbers; CR complete remission; PR partial response; Ref references; CRS cytokine release syndrome; ICANS immune effector cell-associated neurotoxicity syndrome; NA not available; Flu fludarabine; Cy cyclophosphamide; MTZ mitoxantrone; MLFS morphologic leukemia-free state.
Table 3. AML target antigens.
Table 3. AML target antigens.
Target AntigensType of MoleculeRoleOn
HSCs		On
LSCs		On AML
Blasts (% of AML Cases)		References
CD7Ig superfamily/GlycoproteinB and T-cell lymphoid
development, transmembrane
protein		NoYesYes
30%		[39]
CD33SIGLEC
Family		Transmembrane receptorYesYesYes
90%		[40]
CD70Member of the TNF-alpha familyTransmembrane proteinNoYesYes
≥90%		[41]
CD84Immunoreceptor member of SLAM familyTransmembrane receptorNoYesYes
99%		[42]
CD93C-TYPE lectin transmembrane receptorCell-adhesion processNoYesYes[43]
CD123Type I cytokine receptor of
IL-3		IL-3 receptor α subunitYesYesYes
97%		[44,45]
CLL1Type II transmembrane glycoproteinTransmembrane receptorNoYesYes
92%		[46]
FLT3Type III cytokine receptorTyrosine kinase receptorYesYesYes
30%		[47]
FRβFolate-binding protein
receptor		Folate deliveryNoYesYes
70%		[48]
h8F4Peptide derived from the leukemia-associated antigens proteinase 3HLA-presented antigensNoNoNo
≥90%		[49]
LILRB4Leukocyte Ig-like Receptor-B
Family		Inhibitory receptor role in immune
tolerance		NoYesYes
≥90%		[50]
NKG2DC-type lectin-like receptor
Protein		Activator receptorNoYesYes
NKG2D ligands 67–100%		[51,52]
Siglec-6SIGLEC
Family		Transmembrane receptorNoNoYes70%[53]
TIM-3T-cell immunoglobulin mucin-3Immune checkpoint proteinNoYesYes78%[54]
WT1Zinc-finger DNA binding
Protein		Transcription factorNoNoYes
80–90%		[55]
Abbreviations: AML acute myeloid leukemia; HSCs hematopoietic stem cells; LSCs leukemic stem cells; SIGLEC sialic acid binding immunoglobulin-like lectin; TNF tumor necrosis factor; NKG2D natural killer group 2 D; FLT3 fms-like tyrosine kinase 3; FRβ folate receptor β; WT1 Wilms tumor 1.
Table 4. ASTCT CRS consensus grading.
Table 4. ASTCT CRS consensus grading.
CRS ParameterGrade 1Grade 2Grade 3Grade 4
FeverTemperature ≥ 38 °CTemperature ≥ 38 °CTemperature ≥ 38 °CTemperature ≥ 38 °C
HypotensionNoneNot requiring vasopressorsRequiring vasopressor with or without vasopressinRequiring multiple vasopressors (excluding vasopressin)
And/or
HypoxiaNoneRequiring low-flow nasal cannula or blow-byRequirinh high-flow nasal cannula, facemask, nonrebreather mask or Venturi maskRequire positive pressure (CPAP, BiPAP, intubation and mechanical ventilation)
Table 5. ASTCT ICANS consensus grading for adults.
Table 5. ASTCT ICANS consensus grading for adults.
Neurotoxicity
Domain		Grade 1Grade 2Grade 3Grade 4
ICE score *7–93–60–20 (patient is unarousable and unable to perform ICE)
Depressed level of consciousnessAwakens spontaneouslyAwakens to voiceAwakens only to tactile stimulusPatient is unarousable or requires vigorous or repetitive
tactile stimuli to arouse. Stupor or coma
SeizureNANANADeep focal motor weakness such as hemiparesis or paraparesis
Motor findingsNANANADeep focal motor weakness such as hemiparesis or paraparesis
Elevated intracranial pressure/cerebral edema Focal/local edema on neuroimagingDiffuse cerebral edema on neuroimaging; decerebrate or decorticate posturing; or cranial nerve VI palsy; or papilledema; or Cushing’s triad
* Immune-effector-cell-associated encephalopathy (ICE) SCORE; Orientation: orientation to year, month, city, hospital: 4 points; Naming: ability to name three objects (e.g., point to clock, pen, button): 3 points; Following commands: ability to follow simple commands (e.g., “Show me two fingers” or “Close your eyes and stick out your tongue”): 1 point; Writing: ability to write a standard sentence (e.g., “Our national bird is the bald eagle”): 1 point; Attention: ability to count backwards from 100 by 10: 1 point; Scoring: 10, no impairment; 7–9, grade 1 ICANS; 3–6, grade 2 ICANS; 0–2, grade 3 ICANS; 0 due to patient unarousable and unable to perform ICE assessment, grade 4 ICANS.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Canichella, M.; Molica, M.; Mazzone, C.; de Fabritiis, P. Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances. Cancers 2024, 16, 42. https://doi.org/10.3390/cancers16010042

AMA Style

Canichella M, Molica M, Mazzone C, de Fabritiis P. Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances. Cancers. 2024; 16(1):42. https://doi.org/10.3390/cancers16010042

Chicago/Turabian Style

Canichella, Martina, Matteo Molica, Carla Mazzone, and Paolo de Fabritiis. 2024. "Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances" Cancers 16, no. 1: 42. https://doi.org/10.3390/cancers16010042

APA Style

Canichella, M., Molica, M., Mazzone, C., & de Fabritiis, P. (2024). Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances. Cancers, 16(1), 42. https://doi.org/10.3390/cancers16010042

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop